Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Myovant nets $135mm through public offering

Executive Summary

Myovant Sciences Inc. (therapies for women's health and prostate cancer) netted $135mm through a public offering of 17.4mm common shares (including the overallotment) at $8.25. Funds will support ongoing Phase III trials with lead candidate relugolix (the LIBERTY trial for uterine fibroids and heavy menstrual bleeding, and the HERO study for advanced prostate cancer), and will also be used to fund potential regulatory filings for the project.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies